Home Innovation That Matters

Innovation That Matters

Congratulations to Foundation Medicine for a Successful IPO

Our warm congratulations to Foundation Medicine on the important milestone of initial public offerings! Located in Cambridge, Massachusetts, Foundation Medicine is a cancer diagnostic biotech company that enables doctors to recommend treatment options for cancer patients based on their genetic profile. WuXi Corporate Venture Fund...

Inside Perspectives on the Discovery of the Hep C Combo Therapy Elbasvir/Grazoprevir

By Rich Soll, Senior Vice President, Research Service Division, WuXi AppTec (@richsollwx) The impact of approved medicines can often overshadow the heroic efforts of the researchers and drug developers that went into the creation of a new therapy. Take for example Hepatitis C, a viral...

Genentech’s New Combination Chemotherapy Prolonged Breast Cancer Patient Lives for Extra 16 Months

A phase III clinical trial sponsored by Genentech using a combination of chemotherapy drugs showed unprecedented results in patients with metastatic HER2-positive breast cancer.  The outcome of this study is published in the February issue of the prestigious New England Journal of Medicine.  The...

FDA Approves Lenvima for Treatment of Progressive Radioiodine-refractory Differentiated Thyroid Cancer (RR-DTC)

FDA announced this February the approval of lenvima (lenvatinib), a novel investigative chemotherapy for patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC).  Lenvima is developed by Eisai Co., Ltd headquartered in Tokyo, Japan.  This approval is one day after the publication of Eisai’s phase...

Improving Gene Editing with Drugs: An Interview with Dr. Sheng Ding

CRISPR/Cas technology adapted from the bacterial immune system has received tremendous attention from medical research and technology community.  With the advent of genomic sequencing and subsequent disease predisposition gene discovery, this technology offers enormous opportunities to correct genetic defects for patients suffering from rare...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Acquires ResearchPoint Global to Better Enable Clinical Development Worldwide

We are pleased to announce that WuXi has acquired ResearchPoint Global (RPG), a U..S-based contract research organization (CRO) with expertise spanning across all major...